Interestingly, treatment with SAHA, bexarotene and CDDP also significantly reduced NCI-H460/CDDP tumor growth, further confirming that the dual targeting of HDAC and RXR reverses CDDP resistance. Here, HDAC9 is linked to neoplasm.